Newsletter #6 (2), 2016
August 2016

As of June 2016 the number of members of our WG is 371.

The WG Board Members met in Vienna, on May 21th, just before the 53rd ERA-EDTA Congress, to plan future activities.

Time for renewal of the WG board has come and a call for application has been launched. Two members will be substituted by the end of the year.

Activity of our WG at the 53rd ERA-EDTA Congress (May 21st to 24th) was remarkable, in particular during the organized CME course and the involvement with the Symposia on MBD. Attendance at these meetings was very good, pointing to the high interest in CKD-MBD. The program of these activities:

CME course “New insights into CKD-MBD” (May 21st).
Part I. Old and new biomarkers in CKD-MBD.
Chairs: Vincent Brandenburg, Aachen, Germany; Ziad Massy, Paris, France
  1. Will Klotho and FGF23 make you change your clinical practice? Marc Vervloet, Amsterdam, The Netherlands
  2. Alkaline phosphatase.  Jordi Bover, Barcelona, Spain
  3. Phosphate. Mario Cozzolino, Milan, Italy
Part II. Too high, too low, defining the optimal PTH level in CKD.
Chairs: Jordi Bover, Barcelona, Spain; Mario Cozzolino, Milan, Italy
  1. What do observational and intervention studies teach us?. David Goldsmith, London, United Kingdom
  2.. PTH resistance in CKD. Pieter Evenepoel, Leuven, Belgium
  3. What is the role of bone biopsy and bone biomarkers?. Pablo Antonio Ureña Torres, Saint-Ouen, France
Symposium 21: Calcification and Calciphylaxis (May 23rd).
Chairs: Hannes Olauson, Stockholm, Sweden; Gernot Schilcher, Graz, Austria
  1. Calcification in heart valves: clinical implications, consequences, therapy. Pablo Antonio Ureña Torres, Saint-Ouen, France
  2. Vascular calcification in CKD patients: evaluation and outcomes. Teresa Adragao, Cascais, Portugal
  3. New insights into the FGF23-Klotho axis. Hannes Olauson, Stockholm, Sweden
  4. Uraemic calciphylaxis - clinical picture, course and therapeutic options. Markus Ketteler, Coburg, Germany
Symposium 55: Gone with Wnt (May 24th).
Chairs: Pieter Evenepoel, Leuven, Belgium; Susan M. Ott, Seattle, U.S.A.
  1. Wnt signaling in vascular calcification. Mario Cozzolino, Milan, Italy
  2. Wnt signaling in bone diseases. Martine Cohen-Solal, Paris, France
  3. Limitations of the current therapies for osteoporosis in patients with CKD. Susan M. Ott, Seattle, U.S.A.
  4. Sclerostin and the CV system. Vincent Brandenburg, Aachen, Germany
Current and upcoming activities
1. A review paper, partly narrative and partly systematic in collaboration with Cochrane Group, on the role of Magnesium in renal patients has been accepted for publication in an important journal.
2. The questionnaire on CUA perception realized during the Leuven meeting became a paper now available on NDT. (
3. In cooperation with the ERA-EDTA working group on Renal Nutrition (ERN), two overview papers have been prepared and are under review. The first deals with Vitamin D Status and its Relationship to Muscle Health and Frailty in Chronic Kidney Disease.  The second covers the relevance of diet and modifications thereof in phosphate homeostasis and potential toxicity.
4. Edited by Pablo Urena a Book on “Vitamin D in Chronic Kidney Disease” (Springer) is in press.
5. A proposal for a review paper on the possible lessons from CKD-MBD that could apply to general population has been submitted to Lancet by Dr. Covic on behalf of the WG.
6. We plan to write an European commentary on the next release of the CKD-MBD KDIGO guidelines
7. As a final plan, presentations at the Amsterdam meeting in September (see below) will be written as original papers by the respective Authors and will be reviewed for publication in a special issue of the Journal of Nephrology.
Cooperation: The CKD-MBD working group is cooperating with:
- the European Society of Pediatric Nephrology in order to develop common specific lines of clinical research in the field of CKD-MBD, spanning both pediatric and adult nephrology.
- The Japanese Society of Nephrology, (JSN) by being represented at each other meetings, share continental experience. In addition, JSN will benefit of European experience in establishing a Working Group on CKD-MBD.
- The European Renal Nutrition (ERN) working group in combining forces on scientific topics at the boundaries of MBD and the nutritional impact on that.

WG Activities:
Calciphylaxis registry. The Internet site ( is now available in several languages for local uses. Approval from local ECs came first from Italy and non -German patients are expected to flow soon into the registry.
B Bone Biopsy Registry. the bone-biopsy network aims at joining nephrologists, endocrinologists and pathologists (Coordinator: Pieter Evenepoel). It is expected to collect the largest possible bone samples to be examined homogeneously, in order to improve knowledge on the role of bone in systemic disease.
C MBD risk prediction score in CKD. Dr. Vervloet and Massy are aiming at evaluating data from large registries to develop a score capable of predicting risk attributable to MBD. The analysis will be performed on the EuroDOPPS data set.
Next appointments
On September 2016, in Amsterdam, Dr Vervloet and Dr Massy will host the meeting “Bone in CKD”. Also this will be a CME course with the following program:
  a. Uremic toxicity and CKD bone. Masafumi Fukagawa
  b. Bone biopsy: Procedure, indications and histomorphometry anno 2016. Pieter Evenepoel
  c. Changing Bone Patterns with Progression of Chronic Kidney Disease.  Ziad Massy
  d. Interpretation of DEXA Micro CT in CKD and dialysis. Marie Helene Lafage
  e. Circulating markers of bone turnover. Marc Vervloet
  f. Bone histology based treatment. Patrick D’Haese and Pieter Evenepoel
  g. Evaluation of fracture (risk) in CKD. Martine Cohen-Solal and Pablo Urena
  h. Vitamin D and Osteoporosis in CKD. Paul Lips
  i. Current treatments: bisphosphonates, estrogen, vitamin D, calcium and raloxifen. Mario Cozzolino
  j. Positioning novel biologicals in CKD. Sandro Mazzaferro
The fourth workshop on CKD-MBD previously scheduled to be held on December 2016 in Milan, Italy, will be postponed to 2017 (date to be established).
C CME course and Symposia for the next ERA-EDTA congress in Madrid, May 2017 are under preparation.
CKD-MBD related publications in NDT and CKJ
As a contribution of ERA-EDTA communication team, we are again reporting on the most recent papers published on the journals of our society and dealing with CKD-MBD. The content of this third group of papers is reported in a separate link
Clinical Kidney Journal (CKJ)
The possibility of submitting papers to CKJ free of charge submission fees,
continues up to the end of the year! Run to submit original papers!